Design Therapeutics (DSGN) Free Cash Flow (2020 - 2026)
Design Therapeutics (DSGN) reported Free Cash Flow of -$16.4 million for Q1 2026, up 2.55% on a YoY basis from -$16.0 million in Q1 2025, and down 36.93% sequentially from -$12.0 million in Q4 2025.
Design Therapeutics (DSGN) Free Cash Flow (2020 - 2026) Analysis & Trends
Design Therapeutics (DSGN) has 7 years of Free Cash Flow data on file, last reported at -$16.4 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow rose 2.55% year-over-year to -$16.4 million; the trailing twelve-month figure through Mar 2026 stood at -$54.1 million (down 13.53% YoY), and the FY2025 full-year result was -$54.6 million, down 25.56% from the prior year.
- Free Cash Flow eased to -$16.4 million in Q1 2026, from -$12.0 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$9.5 million in Q3 2024 to a low of -$17.5 million in Q1 2023.
- A 5-year average of -$13.2 million and a median of -$12.6 million in 2024 frame the typical range for Free Cash Flow.
- Across the five-year window, Free Cash Flow sank 217.59% in 2022 and jumped 34.67% in 2024, its largest moves.
- Tracing DSGN's Free Cash Flow over 5 years: stood at -$16.0 million in 2022, then climbed by 21.04% to -$12.6 million in 2023, then grew by 21.71% to -$9.9 million in 2024, then decreased by 21.7% to -$12.0 million in 2025, then slumped by 36.93% to -$16.4 million in 2026.
- Business Quant data shows DSGN's Free Cash Flow at -$16.4 million in Q1 2026, -$12.0 million in Q4 2025, and -$11.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | Design Therapeutics | 714.48 Mn | 491.66 Mn | - | -16.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.43 Mn |
| Mar 31, 2026 | -16.43 Mn |
| Dec 31, 2025 | -12.00 Mn |
| Dec 31, 2025 | -12.00 Mn |
| Sep 30, 2025 | -11.16 Mn |
| Sep 30, 2025 | -11.16 Mn |
| Jun 30, 2025 | -14.53 Mn |
| Jun 30, 2025 | -14.53 Mn |
| Mar 31, 2025 | -16.86 Mn |
| Mar 31, 2025 | -16.86 Mn |
| Dec 31, 2024 | -9.86 Mn |
| Dec 31, 2024 | -9.86 Mn |
| Sep 30, 2024 | -9.53 Mn |
| Sep 30, 2024 | -9.53 Mn |
| Jun 30, 2024 | -11.42 Mn |
| Jun 30, 2024 | -11.42 Mn |
| Mar 31, 2024 | -12.63 Mn |
| Mar 31, 2024 | -12.63 Mn |
| Dec 31, 2023 | -12.59 Mn |
| Dec 31, 2023 | -12.59 Mn |